The potential value of tumor mutational burden (TMB) and/or programmed cell death ligand 1 (PD-L1) expression biomarkers to enhance the prediction of which patients are most likely to respond to checkpoint inhibitors that target programmed cell-death protein or PD-L1 has been explored in multiple studies [3–6]. The gene discussed is CD274; the disease is neoplasm.